COVID-19 vaccines are usually safe. They may cause some side effects such as injection-site pain, fatigue, headache, fever and allergic reactions.

India covid Vaccine survey reveals that link below

https://qz.com/india/1955966/questions-over-indias-covaxin-side-effects-ethical-violations/amp/

https://indianexpress.com/article/lifestyle/health/indians-covid-19-vaccine-survey-7109653/lite/

I am intertesting

COVID-19 vaccines are usually safe. They may cause some side effects such as injection-site pain, fatigue, headache, fever and allergic reactions.

Serious side effects are similar to those in the placebo group. There are usually mild side effects.

Please see the related link:

Article Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Dear Serdar Kalemci

You can't really estimate side effect of the vaccine in mid to long term perspective based on limited clinical trials. By limited I also mean limited in time, I also mean limited in population analysis, I also mean limited in analysis on specific antibodies types, groups, subgroups, germlines of produced antibodies at the specific time points after vaccine administering, I also mean limited in previous immune status analysis of vaccinated individuals. This limitations often apply to many vaccines and not only related to SARS-CoV-2 vaccines, but in this particular case, because of essence of the disease, its pathogenesis pathways - the approach should be far more accurate than "usual".

Best Regards,

Mikhail Fedorov

DearMikhail Fedorov, please have a look at the following link:

https://www.aarp.org/health/conditions-treatments/info-2020/coronavirus-vaccine-side-effects/

Dear Mikhail Fedorov, the following link might help you, please have a look:

https://www.nhsinform.scot/healthy-living/immunisation/vaccines/coronavirus-covid-19-vaccine/side-effects-of-the-coronavirus-vaccine

We can’t say that vaccine is effective 100% on population,there r many side effects which can’t be estimated by limited population,time or clinical trial analysis.

Of course, there are many unanswered questions, but at the moment (mid-January 2021) no serious negative side effects have been shown to a significant extent. The currently used vaccines are recognized as highly effective (eg Pfizer 95 percent, Moderna 94 percent effective, according to tests carried out by the pharmaceutical companies producing these vaccines). Let us hope that thanks to these vaccines and the initiated vaccination programs of citizens, in 2021 mankind will be able to solve this global problem of health, social, economic etc.

Regards,

Dariusz Prokopowicz

Potential side effects could be headaches, fever, general weakness, etc.

Is it coincidence that the recently reported escape mutants of the SASCoV2 virus emerged from three countries that had large vaccination trials, South Africa, Brazil and UK. Could immune pressure of this vaccine cause intrapatient escape mutants evolved from the millions of viral quasi-species produced during viral replication, E484K and N501Y?

Alternatively, is this a confounding factor where genetic sequencing is more prevalent where vaccine trials are occurring?

Should we also be concerned about further genetic recombination from other RNA viruses as COVID19 is under pressure to survive?

Dear Annwyne Houldsworth

This is an interesting point of view, I am not sure if vaccine trials are related to recent mutations, but there is a non zero probability of this.

Regarding mutants and current vaccines antiviral targeting action effectiveness:

I think that since current vaccines with unmodified S protein cause the production of a wide range of antibodies in a significantly high titer and because some of those antibodies are extremely potent against virus and because, usually, mutations affect only 1 to few aminoacids - current vaccines will be still very effective in terms of virus elimination and antiviral protection (also part of antibodies produced in response to S protein are pan coronaviral and not even binds to S1-RBD).

So real concern from mutations is - different infectivity potential. As an example I can give an S1/S2 cleavage site of S protein. It is a pretty much small fragment and mutations there may cause even more easier fusion, and I think even a single aminoacid mutation in that site may visibly affect infectivity.

Best Regards,

Mikhail Fedorov